Wei-tien M. Tai
No. 7, Chung Shan South Road, 100
TPQ, Taiwan
TPQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Corrigendum to "Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity" [Eur. J. Med. Chem. 55 (2012) 220-227].
Journal: European journal of medicinal chemistry
Published: November 09, 2017
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy.
Journal: Oncotarget
Published: August 06, 2017
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 04, 2017
Erratum to: Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma".
Journal: Journal of hepatology
Published: March 18, 2017
Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma".
Journal: Journal of hepatology
Published: January 11, 2017
Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
Journal: Breast cancer research : BCR
Published: January 03, 2017
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis.
Journal: Scientific reports
Published: October 13, 2016
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 18, 2016
SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma.
Journal: Oncotarget
Published: August 20, 2015
Last Updated: 09/26/2026